Trails Edge Capital Partners, LP 13F holdings, Q1 2026
Holdings as of March 31, 2026 · filings on SEC EDGAR · latest filing →
Trails Edge Capital Partners, LP disclosed 26 US equity positions worth $424.9m in its Q1 2026 13F filing. The largest position was PCVX at 9.1% of the reported book, followed by DFTX and LB PHARMACEUTICALS INC.
What did Trails Edge Capital Partners, LP own in Q1 2026? Top 26 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | PCVX VAXCYTE INC | Healthcare | 9.1% | $38.5m | 662,470 | – | |
| 2 | DFTX DEFINIUM THERAPEUTICS INC | Healthcare | 7.7% | $32.9m | 1,738,110 | – | |
| 3 | LB PHARMACEUTICALS INC | 7.7% | $32.5m | 1,319,362 | – | ||
| 4 | MIRM MIRUM PHARMACEUTICALS INC | Healthcare | 7.2% | $30.8m | 333,312 | – | |
| 5 | NRIX NURIX THERAPEUTICS INC | Healthcare | 6.4% | $27.0m | 1,743,220 | – | |
| 6 | XENE XENON PHARMACEUTICALS INC | Healthcare | 6.0% | $25.6m | 440,000 | – | |
| 7 | RVMD REVOLUTION MEDICINES INC | Healthcare | 5.6% | $23.8m | 245,000 | – | |
| 8 | RCUS ARCUS BIOSCIENCES INC | Healthcare | 5.3% | $22.6m | 1,047,935 | – | |
| 9 | IMCR IMMUNOCORE HLDGS PLC | Healthcare | 4.8% | $20.6m | 682,597 | – | |
| 10 | CYTK CYTOKINETICS INC | Healthcare | 4.7% | $19.8m | 300,000 | – | |
| 11 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 3.9% | $16.4m | 701,821 | – | |
| 12 | NGNE NEUROGENE INC | 3.7% | $15.8m | 782,787 | – | ||
| 13 | IVA INVENTIVA SA | 3.5% | $14.8m | 2,657,997 | – | ||
| 14 | IKT INHIBIKASE THERAPEUTICS INC | 3.2% | $13.5m | 8,057,345 | – | ||
| 15 | FDMT 4D MOLECULAR THERAPEUTICS IN | Healthcare | 2.9% | $12.1m | 1,302,917 | – | |
| 16 | XFOR X4 PHARMACEUTICALS INC | 2.5% | $10.6m | 2,571,478 | – | ||
| 17 | IMVT IMMUNOVANT INC | Healthcare | 2.4% | $10.3m | 414,054 | – | |
| 18 | DSGN DESIGN THERAPEUTICS INC | Healthcare | 2.1% | $9.1m | 852,013 | – | |
| 19 | CAMP CAMP4 THERAPEUTICS CORP | 2.0% | $8.6m | 1,939,563 | – | ||
| 20 | NERV MINERVA NEUROSCIENCES INC | 2.0% | $8.5m | 1,419,000 | – | ||
| 21 | PROMIS NEUROSCIENCES INC | 1.7% | $7.1m | 557,103 | – | ||
| 22 | SOL-GEL TECHNOLOGIES LTD | 1.6% | $6.8m | 85,496 | – | ||
| 23 | IPSC CENTURY THERAPEUTICS INC | Healthcare | 1.3% | $5.5m | 2,449,993 | – | |
| 24 | VTVT VTV THERAPEUTICS INC | 1.3% | $5.5m | 139,578 | – | ||
| 25 | FTH SENSEI BIOTHERAPEUTICS INC | 0.9% | $3.9m | 125,000 | – | ||
| 26 | IRD OPUS GENETICS INC | 0.5% | $2.3m | 500,000 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.